-
Posted by
Two Blokes Jun 25 -
Filed in
Stock
-
2 views
Despite a revenue miss, Pfizer's Q1 earnings crushed estimates due to aggressive, structural cost-cutting, signaling a powerful shift towards operational and margin excellence. Management is expanding its cost-savings program to a massive $7.7 billion by 2027, aiming to create a powerful EPS growth story despite flat revenues. Pfizer's non-COVID portfolio is firing on all cylinders, with key drugs like Nurtec and Padcev showing robust double-digit growth, proving underlying business health.
